173 related articles for article (PubMed ID: 27750031)
41. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
42. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
43. An extended pyrrolobenzodiazepine-polyamide conjugate with selectivity for a DNA sequence containing the ICB2 transcription factor binding site.
Brucoli F; Hawkins RM; James CH; Jackson PJ; Wells G; Jenkins TC; Ellis T; Kotecha M; Hochhauser D; Hartley JA; Howard PW; Thurston DE
J Med Chem; 2013 Aug; 56(16):6339-51. PubMed ID: 23889553
[TBL] [Abstract][Full Text] [Related]
44. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex.
Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T
Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804
[TBL] [Abstract][Full Text] [Related]
45. Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells.
Belluti S; Basile V; Benatti P; Ferrari E; Marverti G; Imbriano C
Cell Death Dis; 2013 Aug; 4(8):e756. PubMed ID: 23928695
[TBL] [Abstract][Full Text] [Related]
46. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
47. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
Stacey DW; Hitomi M; Chen G
Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
[TBL] [Abstract][Full Text] [Related]
48. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
49. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
50. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.
Uesaka T; Shono T; Kuga D; Suzuki SO; Niiro H; Miyamoto K; Matsumoto K; Mizoguchi M; Ohta M; Iwaki T; Sasaki T
J Neurooncol; 2007 Sep; 84(2):119-29. PubMed ID: 17361331
[TBL] [Abstract][Full Text] [Related]
51. DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival.
Zhao H; Yu H; Liu Y; Wang Y; Cai W
Clin Neuropathol; 2008; 27(2):83-90. PubMed ID: 18402387
[TBL] [Abstract][Full Text] [Related]
52. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226.
Wang H; Jiang Zg; Wong YW; Dalton WS; Futscher BW; Chan VT
Biochem Biophys Res Commun; 1997 Aug; 237(2):217-24. PubMed ID: 9268689
[TBL] [Abstract][Full Text] [Related]
53. The effects of 1,4-benzoquinone on c-Myb and topoisomerase II in K-562 cells.
Singh R; Winn LM
Mutat Res; 2008 Oct; 645(1-2):33-8. PubMed ID: 18778717
[TBL] [Abstract][Full Text] [Related]
54. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
55. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
Hirota H; Gosky D; Berger NA; Chatterjee S
Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
Kitdumrongthum S; Reabroi S; Suksen K; Tuchinda P; Munyoo B; Mahalapbutr P; Rungrotmongkol T; Ounjai P; Chairoungdua A
Biomed Pharmacother; 2020 Jul; 127():110149. PubMed ID: 32344256
[TBL] [Abstract][Full Text] [Related]
57. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
[TBL] [Abstract][Full Text] [Related]
58. Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIalpha gene.
Falck J; Jensen PB; Sehested M
J Biol Chem; 1999 Jun; 274(26):18753-8. PubMed ID: 10373491
[TBL] [Abstract][Full Text] [Related]
59. Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells.
Isaacs RJ; Harris AL; Hickson ID
J Biol Chem; 1996 Jul; 271(28):16741-7. PubMed ID: 8663303
[TBL] [Abstract][Full Text] [Related]
60. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
